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Abstract
The first cases of early-onset progressive polyneuropathy appeared in the Alaskan Malamute population in Norway in the
late 1970s. Affected dogs were of both sexes and were ambulatory paraparetic, progressing to non-ambulatory tetraparesis.
On neurologic examination, affected dogs displayed predominantly laryngeal paresis, decreased postural reactions,
decreased spinal reflexes and muscle atrophy. The disease was considered eradicated through breeding programmes but
recently new cases have occurred in the Nordic countries and the USA. The N-myc downstream-regulated gene (NDRG1) is
implicated in neuropathies with comparable symptoms or clinical signs both in humans and in Greyhound dogs. This gene
was therefore considered a candidate gene for the polyneuropathy in Alaskan Malamutes. The coding sequence of the
NDRG1 gene derived from one healthy and one affected Alaskan Malamute revealed a non-synonymous G.T mutation in
exon 4 in the affected dog that causes a Gly98Val amino acid substitution. This substitution was categorized to be ‘‘probably
damaging’’ to the protein function by PolyPhen2 (score: 1.000). Subsequently, 102 Alaskan Malamutes from the Nordic
countries and the USA known to be either affected (n = 22), obligate carriers (n = 7) or healthy (n = 73) were genotyped for
the SNP using TaqMan. All affected dogs had the T/T genotype, the obligate carriers had the G/T genotype and the healthy
dogs had the G/G genotype except for 13 who had the G/T genotype. A protein alignment showed that residue 98 is
conserved in mammals and also that the entire NDRG1 protein is highly conserved (94.7%) in mammals. We conclude that
the G.T substitution is most likely the mutation that causes polyneuropathy in Alaskan Malamutes. Our characterization of
a novel candidate causative mutation for polyneuropathy offers a new canine model that can provide further insight into
pathobiology and therapy of human polyneuropathy. Furthermore, selection against this mutation can now be used to
eliminate the disease in Alaskan Malamutes.
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Introduction
The first cases of inherited polyneuropathy in Alaskan
Malamutes were observed in Norway more than 30 years ago.
Polyneuropathy in Alaskan Malamutes is one of several canine
inherited neuropathies described in 22 breeds of dog that share
many features with the human Charcot-Marie-Tooth (CMT)
group of diseases [1]. CMT in humans is a heterogeneous group of
inherited polyneuropathies characterized clinically by motor
weakness and sensory loss. This group of diseases is named after
the three clinicians who first described it in 1886 but is also known
as hereditary motor and sensory neuropathy (HMSN) [2].
Mutations in more than 40 known genes expressed in Schwann
cells and neurons are known to be causative of CMT, and the
various forms can have an autosomal recessive, autosomal
dominant or X-linked mode of inheritance. The mode of
inheritance together with the measured motor and sensory nerve
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conduction velocity (NCV) provides the basis for classification of
the CMT phenotypes into several subgroups [3].
A novel autosomal recessive HMSN was first described in
a small gypsy community of Lom in Bulgaria, and designated
Hereditary Motor and Sensory Neuropathy-Lom (HMSNL) [4].
This neuropathy has a childhood onset and initial presentation as
a gait abnormality with progression to limb weakness, sensory loss,
skeletal deformities most notably in the feet, and deafness.
Neuropathological changes within peripheral nerve biopsies
include severe depletion of myelinated nerve fiber populations,
and in younger subjects, hypertrophic changes including onion
bulb formations [5]. The HMSNL locus was mapped to a narrow
interval on human chromosome 8q24 [4], where the causative
mutation was subsequently found to be a nonsense mutation at
amino acid residue 148 in the N-myc downstream-regulated gene
1 (NDRG1) by Kalaydjieva et al. [6]. An inherited polyneuropathy
in which the causative mutation is a 10 bp deletion in exon 15 of
NDRG1 has recently been identified in Greyhound dogs. This
mutation gives rise to a frameshift and a protein which is longer
than the wild type protein [7]. The onset of clinical signs is at three
to nine months of age and includes exercise intolerance, pro-
gressive ataxia, muscle atrophy and inspiratory stridor.
The first cases of polyneuropathy in the Alaskan Malamute
population appeared in Norway in the late 1970’s. Onset of signs
was noticed in seven- to 18-months-old dogs. Affected dogs were of
both sexes. Presenting clinical signs were exercise intolerance,
inspiratory stridor and pelvic limb ataxia. Gait abnormalities
progressed to ambulatory paraparesis, in some cases deteriorating
to non-ambulatory tetraparesis. Additional examinations revealed
decreased postural reactions, decreased to absent spinal reflexes,
muscle atrophy and laryngeal paresis. On electromyography
(EMG) testing, moderately to severely affected dogs and/or
protracted cases had diffuse spontaneous activity, such as
fibrillation potentials and positive sharp waves, in proximal and
distal muscles in all four limbs. In addition, decreased motor nerve
conduction velocities were found. The only aberrant finding on
electrophysiology testing in mild and/or early cases was sponta-
neous activity in EMG of interosseus muscles [8–10]. Based on
pedigree studies and the result of a test mating, it was suggested
that polyneuropathy in Alaskan Malamutes was inherited in an
autosomal recessive manner, and the disease was consequently
named ‘‘hereditary polyneuropathy of Alaskan Malamutes’’
(AMPN) [9–10]. More recently, a number of North American
cases expressing many similarities to those seen in Norway were
described [11].
AMPN was considered to be virtually eradicated in Scandinavia
through breeding programmes as new cases had not been reported
for many years. However, a case of AMPN was diagnosed in
Denmark in 2009, indicating that the disease had reappeared in
Scandinavia. Single cases of AMPN had also occurred in Norway
and Sweden during the last decade. The Scandinavian Alaskan
Malamute Polyneuropathy survey including research partners
from Denmark, Norway and Sweden was therefore initiated in
2010 and has later been extended by collaboration with
researchers in Finland and the USA. The main focus for this
research was to identify the genetic basis for AMPN.
Results
Clinical Characterization of Affected Dogs
Onset of clinical signs was noticed from the age of three to 19
months, (median, 13.5 months). As presenting clinical signs, voice
changes and/or noisy breathing predominated - in some cases in
combination with paraparesis. A few affected dogs expressed
paraparesis as the only presenting clinical sign. Typically, clinical
signs slowly progressed to exercise intolerance, gait abnormalities
and inspiratory stridor, suggesting the presence of laryngeal paresis
or paralysis. Gradually, gait abnormalities progressed from
paraparesis and ataxia to tetraparesis and abnormal pelvic limb
movements of a ‘‘bunny-hopping’’ nature. Many of the affected
dogs had difficulty standing and walking up stairs and eventually
collapsed. With progression of the disease, the dogs developed
muscle atrophy, primarily in the pelvic limbs, but also in the
paraspinal musculature. Electrophysiology testing was in accor-
dance with the results reported by Moe and Bjerka˚s [9] and Moe
[10]. All tested dogs had fibrillation potentials and positive sharp
waves in several muscles at EMG testing. The majority of cases
tested had reduced motor nerve conduction velocities, with inter-
individual variation interpreted as a reflection of the severity and
stage of disease.
Characteristic histopathological findings in the cranial tibial
muscle and fibular nerve are shown from two Alaskan Malamutes
(Figure 1). The pattern of muscle fiber atrophy is typical of
denervation with angular atrophied fibers occurring in small and
large groups and involving both muscle fiber types. Fiber type
grouping, indicative of reinnervation, was an inconsistent finding
depending on the chronicity of the clinical signs. Variable nerve
fiber loss, endoneurial fibrosis and axonal degeneration were
consistently found in the fibular nerve and within intramuscular
nerve branches.
Sequencing
Since NDRG1 is mutated in Greyhounds with a similar
polyneuropathy, this gene was considered a candidate gene for
AMPN. The coding sequence of the canine NDRG1 is 1152 bp
long and comprises 15 exons encoding a protein of 384 amino
acids. Except for an inter species variation in the sequence length
of exon 15, the coding sequence is well conserved (94.7% sequence
similarity) in mammals (see Figure 2 for a multiple protein
alignment). The sequencing of the coding regions in one AMPN-
affected and one healthy Alaskan Malamute revealed synonymous
mutations in exon 1 and 9 and a single non-synonymous G.T
(basepair 293) substitution in exon 4. The mutation in exon 4
causes a Gly98Val amino acid substitution which was predicted to
be probably damaging to the protein function with a score of 1.000
(sensitivity: 0.00; specificity: 1.00) by PolyPhen-2 [12]. To confirm
that the mutation resides in a transcribed region of the gene, the
canine NDRG1 transcript was also sequenced revealing the same
sequence length and amino acid sequence (JX987297).
Genotyping
A total of 102 Alaskan Malamute dogs from Denmark, Norway,
Sweden, Finland and the USA known to be either healthy (n = 73),
obligate carriers (healthy parents of affected offspring) (n = 7) or
diagnosed with AMPN (n = 22) were genotyped for the G.T
substitution. All affected Alaskan Malamutes had the T/T
genotype. The healthy dogs had the G/G genotype except for
13 which had the G/T genotype. All obligate carriers had the G/
T genotype. These results indicate complete co-segregation of the
mutation with the disease according to an expected autosomal
recessive mode of inheritance. Another 201 dogs representing 38
other breeds all had the G/G genotype (see S1 for a list of breeds).
Among these, two Leonberger and two Siberian Huskies were
diagnosed with polyneuropathy. Four Alaskan Malamutes with
neurological signs caused by other diseases (cauda equina
syndrome, cervical cord lesion, diabetes and inflammatory
polyneuropathy respectively) also had the G/G genotype.
Polyneuropathy in Alaskan Malamutes
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Discussion
Identification of the genetic basis for AMPN will allow for
establishment of an appropriate breeding programme and is
therefore beneficial to the general health of the Alaskan Malamute
breed. Moreover, this study also highlights the advantages of dogs
for comparative genetic studies. Dogs are medically surveyed on
a regular basis and the dog population consists of several partially
inbred breeds with known, and from time to time new, genetic
disorders segregating in most of the breeds. When considering the
extensive amount of dog genome resources and rapidly increasing
technologies, canine disorders have a great potential for serving as
models for analogous human diseases [13].
Various forms of inherited motor and sensory neuropathies
have been identified in 22 different dog breeds over the past 50
years [1]. A causative mutation has only been identified in
Greyhound dogs with a mutation in the NDRG1 gene [7].
Our results and observations support the theory that the
mutation identified in Alaskan Malamutes causes AMPN: The
clinical signs in Greyhound dogs and Alaskan Malamutes with
polyneuropathy are comparable. The nonsynonymous G.T
substitution causes the substitution (Gly98Val) of a residue that
is conserved in mammals and this mutation was predicted to be
‘‘probably damaging’’ by PolyPhen-2. It is therefore reasonable to
expect this substitution to have an effect on the function of the
protein.Affected dogs were homozygous for the mutation, obligate
carriers were heterozygous and healthy dogs were homozygous for
Figure 1. Muscle and peripheral nerve pathology in Alaskan Malamutes with polyneuropathy and a mutation in NDRG1.
Representative cranial tibial muscle and peroneal nerve biopsy transverse sections from a two year old female Alaskan Malamute (a,b) and a three
year old female Alaskan Malamute (c,d) with histopathological findings consistent with polyneuropathy. Large and small groups of atrophic fibers
were present with variable severity and fatty infiltration (a,c. H&E stain). A moderate to marked depletion of myelinated fibers was evident in resin
embedded nerve biopsy sections (b,d. Toluidine blue stain). Nerve fiber loss resulted from chronic axonal degeneration (arrows in b,d).
doi:10.1371/journal.pone.0054547.g001
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the wild type allele (except for 13, which were heterozygous). This
is in concordance with autosomal recessive inheritance and also
supports the result of the test mating made in Norway in 1983
[10]. Moreover, the fact that NDRG1 is also mutated in
Greyhounds and humans with some forms of polyneuropathy
supports the hypothesis that the G.T substitution causes AMPN.
If this SNP did not cause disease, it might have existed in other
breeds as well. However, it was not detected in any of the 201 dogs
representing 38 other breeds. The four Alaskan Malamutes with
polyneuropathy with other aetiologies than AMPN illustrate that
phenocopies have to be taken into consideration also with this
disease. One could speculate that this mutation is not causative but
in linkage disequilibrium with another causative mutation in the
same region. Therefore protein coding genes within 5MB
surrounding the NDRG1 gene were scrutinized using the
annotation in the UCSC browser in the human orthologous
region on chromosome 8 (UCSC Human Feb. 2009 (GRCh37/
hg19)). In addition to NDRG1 a total of 13 protein coding genes
are annotated in this region. Considering the functional annota-
tion only one gene, KCNQ3 (potassium channel, voltage-gated,
KQT-like subfamily, member 3), is a potential candidate gene.
However, since this gene is primarily important for cognitive
function and epilepsy [14] we have not studied it further in the
context of polyneuropathy in Alaskan Malamutes.
Figure 2. Multiple alignment of mammalian NDRG1 proteins. Alignment of NDRG1 protein sequences from five mammalian species: Homo
sapiens, Pan troglodytes, Canis lupus, Bos taurus and Mus musculus shows a sequence similarity of 94.7%. Residue 98 (gly, marked with a frame)
which is substituted in Alaskan Malamutes with the G.T mutation, is conserved in the five species.
doi:10.1371/journal.pone.0054547.g002
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Rentmeister et al. [15] recently described AMPN as a polygenic
hereditary disease with variable phenotypic expression. However,
their diagnostic criteria were very broad and ranged from
subclinical forms with signs of marginal degenerative polyneuro-
pathy (based on histopathology) to severe cases supported by EMG
and histopathology. Age of onset for dogs in their study varied
from seven months to 12 years. In our study the dogs are
phenotyped as ‘‘affected’’ only when presenting with the
characteristic clinical signs and a defined age of onset (three to
19 months) and most cases were confirmed with histopathology.
When using these criteria, we found 100% accordance with the
genotyping results and the hypothesis of autosomal recessive
inheritance.
A mouse model, stretcher, with total Ndrg1 deficiency (in frame
deletion of Ndrg1 exons 10–14) shows clinical signs characterized
by tremor and progressive paralysis of the pelvic limbs from the
age of five weeks. Histological examinations reveal demyelination
and axonal degeneration of peripheral nerves [16]. Even though
the same gene is mutated in the stretcher mouse and the Alaskan
Malamutes, the different mutations in two different species are
likely to have different effects on NDRG1 function that in turn
result in phenotypes that are not completely comparable.
Although the stretcher and the AMPN phenotypes have different
characteristics, the progressive paralysis of the pelvic limbs and
axonal degeneration are observed in both species which further
supports the association between this phenotype and mutations in
NDRG1.
NDRG1 is ubiquitously expressed in various tissues in humans
[17] and in rodents and the highest mRNA level is found in the
sciatic nerve [18]. Berger et al. [18] furthermore show that the
NDRG1 is not expressed in the motor and sensory neurons but
highly expressed in Schwann cells where its expression increases
shortly after birth and declines in the adult nerve. Axonotomy
causes NDRG1 downregulation indicating an axon-Schwann cell
integrity dependent expression [18]. These results show that
NDRG1 is important not only for myelination but also for the
maturation and maintenance of the neuron. In both the stretcher
mouse and human cases of HMSNL the demyelination is thought
to cause secondary axonal degeneration. In our study of Alaskan
Malamutes axonal degeneration without demyelination was
observed which also suggests NDRG1 to be central in de-
velopment and maintenance of the axon.
Inherited polyneuropathy in Greyhound dogs may have an
earlier clinical onset (three to nine months) compared to both the
AMPN cases of this study (three to 19 months, median: 13.5
months) and in previous studies (seven to 19 months) [7,10,11].
Otherwise the clinical and histological findings are similar. One
could speculate that the earlier onset in Greyhound dogs is a result
of the frameshift mutation having a more severe impact on the
protein function than the amino acid substitution observed in
Alaskan Malamutes. In both breeds other contributing factors such
as the environment, hormonal influences or modifying genes may
influence the age of onset and the severity of the disease in
individual dogs.
We conclude that the G.T substitution is almost certainly the
mutation that causes AMPN.
Since the same mutation is found in affected Alaskan
Malamutes from Denmark, Norway, Sweden, Finland and USA,
it must have arisen years ago in a common founder. It is therefore
reasonable to believe that the same mutation has also caused
AMPN in the first Alaskan Malamutes diagnosed by Moe and
Bjerka˚s [9] and by Braund et al. [11].
Materials and Methods
Ethics Statement
All samples were collected by veterinarians from privately
owned dogs with consent from the dog owners and in accordance
with the institutional guidelines for animal welfare and ethics. No
ethics committee approval was required as the study was
conducted in cooperation with veterinarians at small animal
clinics and all diagnostic procedures would have been carried out
anyway.
Animal Material
A total of 102 Alaskan Malamute dogs from Denmark, Norway,
Sweden, Finland and the USA known to be either healthy
(control), obligate carriers or diagnosed with AMPN were included
in the study. Control dogs and obligate carriers were checked by
veterinarians in the research group. None of those dogs displayed
any neurological gait deficits. Affected dogs (n = 22) had a clinical
presentation in accordance with AMPN, as described in the results
section (clinical characterization). Electrophysiology testing, per-
formed in 16 affected dogs, was consistent with polyneuropathy. In
addition, in the majority of the cases the diagnosis was confirmed
by histopathology on nerve- and muscle biopsies (n = 13) or post
mortem samples of the same tissues (n = 1). Moreover, a panel of
201 DNA samples representing 38 different dog breeds (see S1 for
a list of breeds) were included to investigate the genotype in other
breeds.
Another four Alaskan Malamutes (two from Norway, two from
the USA) were presented to veterinarians in the research group for
neurological problems, but were excluded from this study. They
were all diagnosed with diseases other than AMPN, explaining
their neurological signs (cauda equina syndrome, cervical cord
lesion, diabetes and inflammatory polyneuropathy respectively)
but were genotyped anyway.
Muscle and Nerve Biopsies
Biopsies (cranial tibial muscle and fibular nerve) were collected
under general anesthesia or in conjunction with euthanasia using
an open biopsy procedure. Unfixed muscles were shipped under
refrigeration by an express service to a specialized laboratory.
Following receipt of tissues, unfixed muscles were flash frozen in
isopentane pre-cooled in liquid nitrogen and stored at 280uC until
further processed. Following cryosectioning, a standard panel of
histochemical stains and reactions including fiber typing was
performed on each muscle [19]. Fixed muscle were immersed into
10% neutral buffered formalin, processed routinely and stained
with hematoxylin and eosin. Fixed nerve biopsies were resin
embedded and evaluated in semi-thin (1 mm) sections.
Isolation of DNA
EDTA stabilized blood samples were collected from 297 of the
dogs. DNA was extracted using a salt precipitation method [20].
In 10 cases for which muscle biopsies were evaluated in cryostat
sections, DNA was extracted from frozen archived tissue using the
DNEasy Blood & Tissue Kit, Qiagen (Hilden, Germany) following
the manufacturer’s recommendations.
Sequencing of NDRG1 Exons in Genomic DNA
Each of the 15 exons were PCR amplified one by one in one
affected and one healthy dog as described previously [7]. Five ml of
each PCR product were run on a 1.5% agarose gel to evaluate the
purity and specificity of the PCR reactions. The PCR products
were purified using MilliporeTM Montage PCR96 Cleanup Kit
(Billerica, Middlesex County, Massachusetts, USA) according to
Polyneuropathy in Alaskan Malamutes
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the manufacturer’s recommendations. Two sequencing reactions,
one for each primer, were made for all PCR products using Big
DyeH Terminator v3.1 Cycle Sequencing Kit, Applied Biosystems
(Foster City, California, USA) and following the manufacturer’s
instructions. The sequencing products were purified using
MilliporeTM Montage SEQ96 Sequencing Reaction Cleanup Kit
(Billerica, Middlesex County, Massachusetts, USA) according to
the manufacturer’s instructions. Sequencing was done using ABI
PRISMH 3130 Genetic Analyzer, Applied Biosystems (Foster City,
California, USA).
Sequencing of the Canine NDRG1 Transcript
After euthanasia of two Belgian Shepard dogs (not affected with
polyneuropathy), brain tissue was sampled and snap frozen in
liquid nitrogen. RNA was isolated using Qiagen RNeasy Lipid
Mini kit (Qiagen, GmbH, Hilden, Germany) following the
manufacturer’s recommendations. cDNAs were synthesized from
1 mg of total RNA using ImProm-IITM Reverse Transcription
System (Promega, Madison, Wisconsin, USA) and a mixture of
random hexamers: oligodT in a ratio of 3:1, according to the
manufacturer’s recommendations.
For amplification of the NDRG1 transcript two pairs of primers
were designed using Primer 3 software [21]: the 59 UTR primer
was designed from a cDNA clone sequence (DN377072.1) (59UTR
L: 59-TTCGGCAGGTGACAGCAG-39), the 39 UTR primer was
designed from a cDNA clone sequence (DN401314.1) (39UTR R:
59-CGTGAGCCCAGAGTCCAG-39) and the two internal pri-
mers were designed from our previously described genomic exon 7
sequence (Exon 7 L: 59-AGGGCCTCGTCCTTATCAAC-39)
and exon 9 sequence (Exon 9 R: 59-GACCACCTC-
CACGTTGTTCT-39). PCR reactions with both primer pairs
were performed on cDNAs generated from the two brain tissue
samples using 2.5 ng/ml cDNA, 2.0 mM MgCl2, Qiagen Hot-
StartTaqHDNA Polymerase (Qiagen, GmbH, Hilden, Germany)
and an annealing temperature of 60uC. Five ml of each PCR
product were run on a 1.5% agarose gel to evaluate the specificity
of the PCR reactions. The PCR products were purified using
GFXTM PCR- and Gel Band Purification Kit (GE Healthcare Life
Sciences, Wauwatosa, Wisconsin, USA).
Two sequencing reactions, one for each primer, were made for
all PCR products using Big DyeH Terminator v3.1 Cycle
Sequencing Kit, Applied Biosystems (Foster City, California,
USA) following the manufacturer’s instructions. The sequencing
products were purified using MilliporeTM Montage SEQ96
Sequencing Reaction Cleanup Kit (Billerica, Middlesex County,
Massachusetts, USA) according to the manufacturer’s instructions.
Sequencing was performed using ABI PRISMH 3130 Genetic
Analyzer, Applied Biosystems (Foster City, California, USA).
Sequence Analysis
For the sequence assembly, analysis, SNP detection and
translation of the cDNA sequence, DNASTAR LasergeneH
SeqMan ProTM (Madison, Wisconsin, USA) was used. Poly-
Phen-2 [12] was used to evaluate the impact of the amino acid
substitution on the protein. Alignment of the human
(NP_001128714.1), the chimpanzee (XP_001140704.1), the ca-
nine (JX987297), the bovine (NP_001030181.1) and the murine
(NP_032707.2) NDRG1 protein sequences was performed using
the AliBee Multiple Alignment tool (http://www.genebee.msu.su/
services/malign_reduced.html).
TaqMan
For genotyping of the remaining dogs, a TaqMan assay was
designed by Applied Biosystems (Foster City, California, USA)
using the following sequence: ACCCAGATGTATTCTTGCCC-
TACTTGTGCCTCTTCTCTCTCTCCCCTGCCTGTTCTC-
CAGACAAAACCTGCTACAACCCCCTCTTCAACTCT-
GAGGACATGCAGGAGATCACACAG-
CACTTCGCCGTCTGCCATGTGGATGCCCCTG(G/
T)CCAGCAGGACGGCGCTGCCTCCTTCCCTGTGGGG-
TAAGACCCGGAGCCTTGTCCCCAGGAGGGGGACAA-
GAAAGCCACGCGGGTGGACTGGGGGTGGGGGGTGC-
GAAGGCAGGCATCACACTGAGT Genotyping was
performed according to the manufacturer’s instructions.
Supporting Information
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